What's AGEMED

AGEMED is an AI-powered mobile application designed to assist in the early detection of Alzheimer’s disease through non-invasive voice analysis and cognitive screening tools. It combines deep learning models with clinically validated cognitive games to offer a scalable, accessible, and cost-effective solution to one of the most pressing challenges in neurology: delayed and subjective diagnosis.

"Speak to detect, live to prevent"

Fighting Against AD

Alzheimer’s disease (AD) affects over 55 million people worldwide, a figure projected to rise sharply in the coming decades. Each case reflects not only a progressive neurodegenerative disorder, but also a delayed diagnosis, limited access to timely care, and significant strain on families and healthcare systems.

Despite advances in neurology, early and accessible detection remains a major unmet clinical need. Current diagnostic methods (such as PET imaging, lumbar punctures, and comprehensive neuropsychological testing) are often invasive, costly, and time-intensive. As a result, Alzheimer’s is frequently identified only after substantial cognitive decline has occurred, narrowing the window for effective intervention.

The consequences are profound: patients lose valuable time for early therapeutic support, while caregivers face increasing emotional, psychological, and logistical burdens.

Accelerating diagnosis means more than early treatment, giving patients more time, families clearer answers, and the dignity of facing Alzheimer’s with clarity, not uncertainty.

At AGEMED, we are committed to developing non-invasive, accessible tools for early detection of Alzheimer’s disease through cutting-edge voice and cognitive analysis technologies. Our goal is to support earlier clinical intervention, reduce diagnostic delays, and provide a more proactive, patient-centered approach to dementia care.

We are dedicated to rigorous clinical validation continuous improvement through expert collaboration, and preparing our AI-driven solutions for real-world use and regulatory approval.

Our Mission

Our Approach

Enabling earlier detection

By fostering collaboration between advanced AI and clinical practice, AGEMED unlocks scalable, real-world solutions, making early detection of Alzheimer’s disease not only smarter but also available to every patient, everywhere.

Reducing costs and time

Improving objectivity

Increasing accessibility

App Functionality

1

2

Voice-Based Screening

Use of deep learning algorithms to analyze spontaneous speech, pauses, articulation, and lexical markers.

3

4

Cognitive Assessment Games

Integrating interactive gamified versions of validated neuropsychological tests to gather additional behavioral and executive function data.

AI Model Architecture

Combinations of Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs/LSTM) to process temporal and acoustic features of recorded voice samples.

Cloud-Based Storage and Analytics

All user data is encrypted and stored securely using Google Firebase, enabling remote updates, real-time analysis, and longitudinal tracking of cognitive performance.

By combining AI-powered voice analysis with validated cognitive testing, AGEMED introduces a smarter, more accessible path to early diagnosis.

Our Partnerships

We are building a collaborative expert network of clinical, academic, and technology partners united by a shared mission: advancing early detection and improving care for Alzheimer’s disease.

If your organization is interested in partnering to accelerate early Alzheimer’s detection, we welcome the opportunity to collaborate. Together, we can deliver scalable, evidence-based solutions to those who need them most.

Cognitive neuroscience research clinics

Universities and research hospitals

Digital health startups and CROs

Foundations and advocacy groups in dementia care

We are actively seeking partnerships with:

Aïcha Díez de Benito | CEO & Founder

Gonzalo Sánchez-Girón | Co-Founder

Our Team

Get in touch

Whether you're a healthcare professional, medical investigator, researcher, investor, or someone affected by Alzheimer’s disease, we’d love to hear from you.

AGEMed is building the future of early detection through AI, and we believe collaboration is key to making this technology accessible to all.